The Future Face of Coinfection
- 1 June 2004
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 36 (2) , 743-749
- https://doi.org/10.1097/00126334-200406010-00012
Abstract
The purpose of this study was to determine the prevalence and incidence of HIV and hepatitis C virus (HCV) coinfection among young (aged 29 years or younger) injection drug users (IDUs) and to compare sociodemographic and risk characteristics between (HIV/HCV) coinfected, monoinfected, or HIV- and HCV-negative youth. Data were collected through the Vancouver Injection Drug Users Study (VIDUS). To date, more than 1400 IDUs have been enrolled and followed, of whom 479 were aged 29 years or younger. Semiannually, participants have completed an interviewer-administered questionnaire and have undergone serologic testing for HIV and HCV. Univariate and multivariate logistic regression analyses were undertaken to investigate predictors of baseline coinfection. Cox regression models with time-dependent covariates were used to identify predictors of time to secondary infection seroconversion. A Cochran-Armitage trend test was used to determine risk associations across 3 categories: no infection, monoinfection, and coinfection. Of the 479 young injectors, 78 (16%) were coinfected with HIV and HCV at baseline and a further 45 (15%) with follow-up data became coinfected during the study period. Baseline coinfection was independently associated with being female, being aboriginal, older age, greater number of years injecting, and living in the IDU epicenter. Factors independently associated with time to secondary infection seroconversion were borrowing needles and greater than once-daily cocaine injection, and accessing methadone maintenance therapy in the previous 6 months was protective. There were clear trends across the 3 categories for increasing proportions of female subjects, aboriginal subjects, older age, greater number of years injecting, living in the IDU epicenter, and daily cocaine use. There were a shocking number of youth living with coinfection, particularly female and aboriginal youth. The median number of years injecting for youth seroconverting to a secondary infection was 3 years, suggesting that appropriate public health interventions should be implemented immediately.Keywords
This publication has 21 references indexed in Scilit:
- Hepatitis C in the HIV-Infected PersonAnnals of Internal Medicine, 2003
- Intentional Nonadherence Due to Adverse Symptoms Associated With Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Management of hepatitis C in human immunodeficiency virus-infected patients.Digestive and Liver Disease, 2002
- Influence of Hepatitis C Virus Coinfection on Lipid Abnormalities in HIV-Positive Patients After Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- HIV incidence and associated risk factors among young injection drug usersAIDS, 2002
- Evolution of Coinfection with Human Immunodeficiency Virus and Hepatitis C Virus in Patients Treated with Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2001
- Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected PatientsAIDS Research and Human Retroviruses, 2001
- Hepatitis C Virus Infection and Needle Exchange Use Among Young Injection Drug Users in San FranciscoHepatology, 2001
- Injection-Related Risk Behaviors in Young Urban and Suburban Injection Drug Users in Chicago (1997–1999)JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York CityAmerican Journal of Public Health, 2001